Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06742723 · ClinicalTrials.gov registry record · Phase 3

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

A Phase 3 study of Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
5,000
Enrollment target
20
Study locations

NCT06742723: Recruiting Phase 3 study of Chronic Kidney Disease and Hypertension, sponsored by AstraZeneca.

NCT06742723 is a Phase 3 study of Chronic Kidney Disease and Hypertension that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 5,000 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (548% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06742723, a Phase 3 study of Chronic Kidney Disease and Hypertension, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
5,000 participants
Enrollment target
20
Study locations

Study Summary

International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

Primary Outcome

Time to the first occurrence of any of the components of the composite of: Kidney disease progression * ≥ 50% sustained decline in eGFR * Onset of kidney failure: * Sustained eGFR \< 15 mL/min/1.73 m2 or * Chronic dialysis treatment or * Receiving a kidney transplant or * Death with a renal primary cause (death due to kidney failure when dialysis is not given) CV events * HF with or without hospitalisation * CV death

Conditions Studied

Chronic Kidney Disease and Hypertension

Interventions

  • DRUG Baxdrostat/dapagliflozin
  • DRUG Placebo/dapagliflozin

Study Locations (20)

California

  • Research Site - Beverly Hills
  • Research Site - Canoga Park
  • Research Site - Concord
  • Research Site - Fremont
  • Research Site - Fullerton
  • Research Site - Inglewood
  • Research Site - Los Alamitos
  • Research Site - Los Angeles
  • Research Site - San Diego
  • Research Site - San Francisco
  • Research Site - Stanford
  • Research Site - Tarzana

Arizona

  • Research Site - Surprise
  • Research Site - Tucson

Colorado

  • Research Site - Arvada
  • Research Site - Denver

Alabama

  • Research Site - Fairhope

Connecticut

  • Research Site - New Britain

District of Columbia

  • Research Site - Washington D.C.

Florida

  • Research Site - Boca Raton

Trial Details

FieldValue
Enrollment Target 5,000 participants
Start Date 2025-03-03
Est. Completion 2029-12-18
Phase Phase 3
AstraZeneca

1,285 total trials

What NCT06742723 shows while recruiting

NCT06742723 is an interventional study that assigns participants to a tested intervention. Its 5,000 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (548% higher).

The record links to 1 condition, with Chronic Kidney Disease and Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Baxdrostat/dapagliflozin is the first listed.

NCT06742723 names 20 study sites across 7 states, led by California, Arizona, Colorado.

Frequently Asked Questions

What is clinical trial NCT06742723 about?

NCT06742723 is a clinical study titled "A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure". International, Multicenter, Double-Blind, Placebo-Controlled and Event-driven study to assess efficacy, safety and Tolerability of Baxdrostat in combination with Dapagliflozin on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure

What is the current status of trial NCT06742723?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 5,000 participants. The study started on 2025-03-03. Estimated completion is 2029-12-18.

What conditions does trial NCT06742723 study?

This clinical trial studies the following conditions: Chronic Kidney Disease and Hypertension.

What interventions are being tested in trial NCT06742723?

The interventions under investigation include: Baxdrostat/dapagliflozin (DRUG), Placebo/dapagliflozin (DRUG).

Who is sponsoring clinical trial NCT06742723?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06742723 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease and Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06742723's enrollment target sits among peer trials

5,000 49th of 2000 higher than 1,950 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00060541 · 5,000 participants

    Evaluation and Treatment of Neurosurgical Disorders

  • NCT00575081 · 5,000 participants

    Physiological Brain Atlas Development

  • NCT00736749 · 5,000 participants

    Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

  • NCT00900198 · 5,000 participants

    Collection of Tissue Samples for Cancer Research

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06742723

Source: ClinicalTrials.gov NCT06742723, the US trial registry maintained by the National Library of Medicine. NCT06742723 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.